Released in 2006 by Merck Healthcare KGaA (Darmstadt, Germany), the easypodTM drug delivery solution was designed to support children undergoing GH therapy for growth disorders (49, 50). This evidence concerns the gene GH1 and hereditary endocrine growth disease.